Your browser doesn't support javascript.
loading
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.
Proud, Pamela C; Tsitoura, Daphne; Watson, Robert J; Chua, Brendon Y; Aram, Marilyn J; Bewley, Kevin R; Cavell, Breeze E; Cobb, Rebecca; Dowall, Stuart; Fotheringham, Susan A; Ho, Catherine M K; Lucas, Vanessa; Ngabo, Didier; Rayner, Emma; Ryan, Kathryn A; Slack, Gillian S; Thomas, Stephen; Wand, Nadina I; Yeates, Paul; Demaison, Christophe; Zeng, Weiguang; Holmes, Ian; Jackson, David C; Bartlett, Nathan W; Mercuri, Francesca; Carroll, Miles W.
Afiliação
  • Proud PC; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Tsitoura D; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia.
  • Watson RJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Chua BY; Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia.
  • Aram MJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Bewley KR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Cavell BE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Cobb R; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Dowall S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Fotheringham SA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Ho CMK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Lucas V; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Ngabo D; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Rayner E; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Ryan KA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Slack GS; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Thomas S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Wand NI; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Yeates P; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.
  • Demaison C; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia.
  • Zeng W; Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia.
  • Holmes I; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia.
  • Jackson DC; Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia.
  • Bartlett NW; Viral Immunology and Respiratory Disease group and Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
  • Mercuri F; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia. Electronic address: fm@enarespiratory.com.
  • Carroll MW; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG; Nuffield Dept of Medicine, Oxford University, Oxford, UK. Electronic address: miles.carroll@phe.gov.uk.
EBioMedicine ; 63: 103153, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33279857
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema Respiratório / Eliminação de Partículas Virais / Receptor 2 Toll-Like / Receptor 6 Toll-Like / Lipopeptídeos / SARS-CoV-2 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: EBioMedicine Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema Respiratório / Eliminação de Partículas Virais / Receptor 2 Toll-Like / Receptor 6 Toll-Like / Lipopeptídeos / SARS-CoV-2 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: EBioMedicine Ano de publicação: 2021 Tipo de documento: Article